ProKidney Corp
PROK1.870USD
+0.140+8.09%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
254.28MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über ProKidney Corp Unternehmen
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
ProKidney Corp Informationen
BörsenkürzelPROK
Name des UnternehmensProkidney Corp
IPO-datumJun 30, 2021
CEOCulleton (Bruce)
Anzahl der mitarbeiter204
WertpapierartOrdinary Share
GeschäftsjahresendeJun 30
Addresse2000 Frontis Plaza Blvd
StadtWINSTON-SALEM
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl27103
Telefon13369997028
Websitehttps://prokidney.com/
BörsenkürzelPROK
IPO-datumJun 30, 2021
CEOCulleton (Bruce)
Führungskräfte von ProKidney Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
+1537020.00%
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Alan M. Lotvin, M.D.
Dr. Alan M. Lotvin, M.D.
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Mr. Jose Ignacio Jimenez Santos
Mr. Jose Ignacio Jimenez Santos
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Bruce Culleton, M.D.
Dr. Bruce Culleton, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.54M
+1537020.00%
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
Andere
60.77%
Aktionäre
Aktionäre
Anteil
Tolerantia LLC
15.98%
Suvretta Capital Management, LLC
8.72%
Control Empresarial de Capitales, S.A. de C.V.
7.58%
Morgan Stanley Investment Management Inc. (US)
4.53%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
Andere
60.77%
Aktionärstypen
Aktionäre
Anteil
Corporation
23.56%
Hedge Fund
11.04%
Investment Advisor
10.26%
Investment Advisor/Hedge Fund
6.12%
Individual Investor
1.83%
Research Firm
0.90%
Endowment Fund
0.71%
Bank and Trust
0.04%
Family Office
0.02%
Andere
45.52%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
178
41.07M
29.01%
-2.81M
2025Q3
180
38.60M
28.59%
-15.99M
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
2023Q3
236
64.28M
104.12%
-21.16M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Tolerantia LLC
22.62M
15.98%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
8.72%
--
--
Sep 30, 2025
Control Empresarial de Capitales, S.A. de C.V.
10.72M
7.58%
+2.28M
+27.04%
Apr 22, 2025
Morgan Stanley Investment Management Inc. (US)
6.41M
4.53%
+698.99K
+12.24%
Sep 30, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.42%
--
--
Oct 31, 2025
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.73%
--
--
Nov 30, 2025
Bleichroeder LP
2.00M
1.41%
--
--
Sep 30, 2025
Millennium Management LLC
1.96M
1.38%
+1.96M
--
Sep 30, 2025
The Vanguard Group, Inc.
1.56M
1.1%
-3.75K
-0.24%
Sep 30, 2025
Culleton (Bruce)
1.54M
1.09%
+1.54M
--
Mar 17, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Schwab U.S. Small-Cap ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Mehr Anzeigen
Schwab U.S. Small-Cap ETF
Anteil0.01%
ALPS Medical Breakthroughs ETF
Anteil0%
Global X Russell 2000 Covered Call ETF
Anteil0%
Schwab U.S. Broad Market ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Avantis US Equity ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
